Should you buy AbCellera Biologics stock now?
Yes, the technical signal for AbCellera Biologics is currently BUY. AbCellera Biologics trades at $6.35 as of 8/6/2026. The overall technical signal is: Buy. The technical analysis shows the following: MACD is negative (bearish trend) at -0.156 with falling momentum (signal: -0.150); RSI is at 48.6 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $10.50 points to 65.5% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for AbCellera Biologics stock?
The average analyst price target for AbCellera Biologics is $10.50. The current price is $6.35, which gives an upside of 65.5%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $9.45 and $11.55.
Is AbCellera Biologics a dividend stock?
No, AbCellera Biologics does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of AbCellera Biologics stock?
AbCellera Biologics is rated as a stock with extreme risk. the annual standard deviation is 77.2%, which classifies the stock as extreme risk.
Is AbCellera Biologics overvalued?
No, AbCellera Biologics is considered undervalued based on the analyst price target (65.5% upside). AbCellera Biologics has the following valuation ratios: a P/S ratio of 23.5, a P/B ratio of 1.9. The analyst price target suggests that the stock is undervalued by 65.5%.
Is AbCellera Biologics overbought?
No, AbCellera Biologics is not overbought. RSI is at 48.6 (neutral zone). The technical indicators show: RSI is at 48.6 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 5.4% above the 20-day average (short-term uptrend). In addition, MACD is negative with falling momentum (bearish).
When is the next AbCellera Biologics earnings report?
The date of the next earnings report for AbCellera Biologics has not been published yet. Check the company's investor calendar for updates.
Is AbCellera Biologics shorted?
Yes, AbCellera Biologics is shorted with 19.1% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. Data is updated daily based on official filings with the SEC.
Are insiders buying AbCellera Biologics stock?
Yes, insiders are net buyers of AbCellera Biologics – they are buying more shares than they are selling. Over the last 3 months, insiders have made 2 purchases and 0 sales. On a net basis, 142,900 $ worth of shares were bought. Across the last 20 reported transactions, the split is 20 purchases and 0 sales, with a net 3,971,137 $ bought. Active buyers include Booth Andrew, Montalbano John S., Thermopylae Holdings Ltd. and others. Insider buying is generally seen as a positive signal, because management is putting its own money into the company.
Is AbCellera Biologics a good stock?
Based on our total score, AbCellera Biologics is rated as a poor stock with a total score of 25 out of 100. The stock scores below average on value, quality and momentum – it sits at the lower end of the market. The score is made up of Value: 20/100, Quality: 2/100, Momentum: 53/100. In addition: analysts see 65.5% upside to the price target; technical signal: Buy. Whether AbCellera Biologics is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for AbCellera Biologics stock?
The outlook for AbCellera Biologics based on current data: the average analyst price target is $10.50 (+65.5%); the stock is in an uptrend (above SMA50 and SMA200). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is AbCellera Biologics stock rising?
AbCellera Biologics is rising right now. The technical indicators show: the price is 5.4% above the 20-day average; MACD is negative with falling momentum (bearish signal); short interest is 19.1% (high – many are betting on a decline); insiders have mostly been buying the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can AbCellera Biologics go?
The average analyst price target for AbCellera Biologics is $10.50, which corresponds to a potential gain of 65.5% from the current price of $6.35. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can AbCellera Biologics fall?
We lack enough history to give a specific floor for AbCellera Biologics. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does AbCellera Biologics do?
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate AbCellera Biologics as an investment.
Did AbCellera Biologics raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from AbCellera Biologics. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is AbCellera Biologics making money or losing money?
No, AbCellera Biologics is currently not making money — the company is losing money with a negative profit margin of -181.7%, a substantial loss. That means the business loses money on every dollar of revenue. For growth stocks investing in expansion this is normal — but it raises the risk if the company does not reach break-even before its capital runs out.
Can AbCellera Biologics go bankrupt?
The bankruptcy risk of AbCellera Biologics is rated as low. Altman Z2 (a model for assessing financial distress) is 4.62 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 4 — which is average. Debt relative to equity is 29% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does AbCellera Biologics have a lot of debt?
No, AbCellera Biologics has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 29%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
